Nothing gave me lasting relief
The combinations below describe only how research themes complement one another and are not a recommendation for combined use
The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
Post-infection gut dysbiosis drives systemic inflammation, leaky gut, and immune dysregulation all of which amplify fatigue, cognitive impairment, and mood instability.3 BPC-157 has been shown in multiple animal studies to: Accelerate healing of the intestinal epithelium4 Reduce gut inflammation and restore tight junction integrity5 Modulate the vagus nerve, which connects gut function to brain and immune signaling6 For long COVID patients dealing with GI symptoms, food intolerances, or fatigue that tracks with gut dysfunction, this mechanism is directly relevant
Scientists first became interested in this peptide because of its potential influence on the bodys longevity mechanisms
